Focal Epilepsy With and Without Secondary Generalization

3

Review clinical trials related to Focal Epilepsy With and Without Secondary Generalization. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies

Psychotic disorders are up to eight times more prevalent in patients with epilepsy compared to the general population. Among them, postictal psychosis (PIP) is a severe complication of focal epilepsy, characterized by a brief psychotic episode emerging days after a seizure. This project investigates a potentially attenuated and under-recognized manifestation-postictal psychotic symptoms (PPs)-that may arise following hospitalization in a video-EEG monitoring unit and might serve as an early indicator for future PIP. The investigators hypothesize that the incidence of PPs is substantially higher than the 3% PIP prevalence reported in the literature and that their occurrence correlates with the intensity of epileptic activity triggered during video-EEG monitoring. The study has three main objectives: (1) to determine the incidence of PPs in patients with drug-resistant focal epilepsy, (2) to identify predictive factors associated with PPs, and (3) to assess the validity of the PQ-16 screening tool in this clinical context. A prospective monocentric study will be conducted in the video-EEG unit of Nancy University Hospital. One hundred and ten patients hospitalized for at least five days will be included. Psychiatric assessments will include standardized clinical interviews, Brief Psychiatric Rating Scale (BPRS) scoring, and self-report questionnaires. These evaluations will take place at three timepoints: baseline (V1), 3-5 days post-discharge (V2), and two months post-discharge (V3). This study aims to facilitate the early identification of PPs and support the development of preventive strategies, ultimately improving psychiatric care and overall management in patients with epilepsy.

Participants needed: 110
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Central Hospital, Nancy, FranceUpdated: May 15, 2026
Eligibility criteria

confirmed diagnosis of drug-resistant focal epilepsy [+2]

Patients presenting with psychotic symptoms at baseline (V1), or who have had re...

Status: Recruiting

Psychological and Psychiatric Assessment in Patients Eligible for Epilepsy Surgery

The aim of the study is to describe the socio-demographic, clinical, psychological, and psychiatric characteristics of patients with drug-resistant focal epilepsy eligible for epilepsy surgery and any changes in these parameters over time after surgery. Additionally, the study seeks to describe the levels of quality of life, dissociative experiences, prevalence of various psychiatric symptoms, irritability, depressive symptoms, anxiety symptoms, and stigma perception in patients with drug-resistant focal epilepsy eligible for epilepsy surgery and any changes over time after surgery.

Participants needed: 180
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaUpdated: Feb 12, 2026Locations: 1
Eligibility criteria

Patients aged 18 or older at the time of enrollment; [+3]

Patients with evident and/or diagnosed cognitive or psychiatric disorders that p...

Status: Recruiting

Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain

Aim of the study is to better characterize the clinical profile of adjunctive cenobamate by collecting data from the current standard clinical practice in France, Germany, and Spain, to describe the real-world clinical response among adult patients affected by focal epilepsy not adequately controlled despite a history of 2 or 3 ASMs before starting treatment with cenobamate (including previous and concomitant ASMs).

Participants needed: 300
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Aziende Chimiche Riunite Angelini Francesco S.p.AUpdated: Sep 19, 2025Locations: 1
Eligibility criteria

Male and female patients ≥18 years old at the time of cenobamate treatment initi... [+5]

Patients who meet any of the contraindications to the administration of cenobama... [+6]